Clinical Trial Update: Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and pharmacokinetics of a fixed-dose combination Brimonidine tartrate 0.025% and Ketotifen fumarate 0.035% ophthalmic solu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Brimonidine tartrate 0.025% / Ketotifen fumarate 0.035% ophthalmic solution (brimonidine tartrate/ketotifen fumarate ophthalmic solution)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2025-07-10